These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


171 related items for PubMed ID: 8599865

  • 1. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve.
    Ghazal-Aswad S, Calvert AH, Newell DR.
    Cancer Chemother Pharmacol; 1996; 37(5):429-34. PubMed ID: 8599865
    [Abstract] [Full Text] [Related]

  • 2. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB, Robinson BA.
    Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.
    Ghazal-Aswad S, Tilby MJ, Lind M, Baily N, Sinha DP, Calvert AH, Newell DR.
    Ann Oncol; 1999 Mar; 10(3):329-34. PubMed ID: 10355578
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K, Gervais A, Aikin A, Egorin M, Balis FM.
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [Abstract] [Full Text] [Related]

  • 5. [Pharmacokinetics of carboplatin in a patient under hemodialysis].
    Kurata H, Yoshiya N, Ikarashi H, Kaneko T, Kodama S, Tanaka K, Suzuki K, Yoshizawa H, Cho T, Suzuki E.
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):547-50. PubMed ID: 8129398
    [Abstract] [Full Text] [Related]

  • 6. Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model.
    Asai G, Ando Y, Saka H, Ando M, Sugiura S, Sakai S, Hasegawa Y, Shimokata K.
    Eur J Clin Pharmacol; 1998 Mar; 54(9-10):725-7. PubMed ID: 9923575
    [Abstract] [Full Text] [Related]

  • 7. Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
    Smit EF, Willemse PH, Sleijfer DT, Uges DR, Postmus PE, Meijer S, Terheggen PM, Mulder NH, de Vries EG.
    J Clin Oncol; 1991 Jan; 9(1):100-10. PubMed ID: 1985158
    [Abstract] [Full Text] [Related]

  • 8. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.
    Peng B, Boddy AV, Cole M, Pearson AD, Chatelut E, Rubie H, Newell DR.
    Eur J Cancer; 1995 Oct; 31A(11):1804-10. PubMed ID: 8541105
    [Abstract] [Full Text] [Related]

  • 9. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
    Peng B, Tilby MJ, English MW, Price L, Pearson AD, Boddy AV, Newell DR.
    Br J Cancer; 1997 Oct; 76(11):1466-73. PubMed ID: 9400943
    [Abstract] [Full Text] [Related]

  • 10. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
    Shen M, Schilder RJ, Obasaju C, Gallo JM.
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
    [Abstract] [Full Text] [Related]

  • 11. [Comparison of pelvic transarterial chemoembolization with lipiodol ultra-fluid carboplatin and transarterial carboplatin through experiment in dogs].
    Chen CL, Sun MH, Tan DC, Liang LZ.
    Ai Zheng; 2004 Nov; 23(11 Suppl):1405-8. PubMed ID: 15566645
    [Abstract] [Full Text] [Related]

  • 12. Carboplatin pharmacokinetics following a single-dose infusion in sulphur-crested cockatoos (Cacatua galerita).
    Filippich LJ, Charles BG, Sutton RH, Bucher AM.
    Aust Vet J; 2004 Jun; 82(6):366-9. PubMed ID: 15267096
    [Abstract] [Full Text] [Related]

  • 13. A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen.
    Panday VR, van Warmerdam LJ, Huizing MT, Rodenhuis S, Schellens JH, Beijnen JH.
    Cancer Chemother Pharmacol; 1999 Jun; 43(5):435-8. PubMed ID: 10100601
    [Abstract] [Full Text] [Related]

  • 14. High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant.
    Colby C, Koziol S, McAfee SL, Yeap B, Spitzer TR.
    Bone Marrow Transplant; 2002 Mar; 29(6):467-72. PubMed ID: 11960264
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A limited sampling method for estimation of the carboplatin area under the curve.
    Sørensen BT, Strömgren A, Jakobsen P, Jakobsen A.
    Cancer Chemother Pharmacol; 1993 Mar; 31(4):324-7. PubMed ID: 8422698
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Validation of the limited-sampling models for carboplatin AUC in combination chemotherapy with taxanes.
    Miyazaki M, Oguri T, Kurata T, Takahashi T, Daga H, Fujitaka K, Isobe T, Nakajima M, Fujiwara Y, Kohno N.
    Anticancer Res; 2004 Mar; 24(3b):1911-4. PubMed ID: 15274375
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.